Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of apoptotic cell clearance. [GOC:obol]
Positive regulation of apoptotic cell clearance is a tightly controlled biological process that ensures the safe and efficient removal of dying cells from the body. This process is crucial for maintaining tissue homeostasis and preventing inflammation.
Here's a detailed description of the process:
1. **Apoptosis Initiation**: The process begins with the activation of intrinsic or extrinsic apoptotic pathways, leading to the activation of caspases and the dismantling of the cell. This dismantling includes:
* **DNA fragmentation**: Caspases cleave DNA into smaller fragments, causing the characteristic ladder-like appearance on electrophoresis.
* **Cell surface changes**: Phosphatidylserine (PS), a phospholipid normally found on the inner leaflet of the cell membrane, is flipped to the outer leaflet.
* **Formation of apoptotic bodies**: The cell breaks down into membrane-bound apoptotic bodies containing cellular components.
2. **Apoptotic Cell Recognition**:
* **PS exposure**: The exposed PS on the apoptotic cell surface acts as an "eat me" signal, recognized by phagocytes.
* **Other signals**: Apoptotic cells also express other molecules like calreticulin, oxidized lipids, and ATP, which further facilitate their recognition by phagocytes.
3. **Phagocytosis**:
* **Engagement of receptors**: Phagocytes express a variety of receptors that recognize the signals on apoptotic cells, including:
* **Phosphatidylserine receptors**: Tim4, BAI1, and other receptors specifically bind to PS.
* **Other receptors**: Macrophages also express receptors for calreticulin, oxidized lipids, and ATP.
* **Internalization**: Upon receptor engagement, phagocytes engulf the apoptotic cell.
4. **Apoptotic Body Degradation**: Once inside the phagocyte, apoptotic bodies are broken down and their components are recycled.
5. **Immune Modulation**: Phagocytosis of apoptotic cells is a critical event in immune regulation, as it prevents the release of intracellular contents that could trigger an inflammatory response. This is achieved by:
* **Anti-inflammatory cytokine production**: Phagocytes release anti-inflammatory cytokines, such as IL-10, to suppress inflammation.
* **Induction of tolerance**: The phagocytosis of apoptotic cells can also induce immune tolerance, preventing the development of autoimmune responses.'
"
Protein | Definition | Taxonomy |
---|---|---|
C-C motif chemokine 2 | A C-C motif chemokine 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P13500] | Homo sapiens (human) |
Complement C3 | A complement C3 that is encoded in the genome of human. [UniProtKB:P01024] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
fasudil | fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia. fasudil: intracellular calcium antagonist; structure in first source | isoquinolines; N-sulfonyldiazepane | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent |
y 27632 | Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme. | aromatic amide | |
ha 1100 | HA 1100: intracellular calcium antagonist | ||
incb3344 | INCB3344: potent and selective small molecule CCR2 chemokine receptor antagonist | ||
compstatin | compstatin: binds to complement 3; amino acid sequence in first source |